CR9518A - Eliminacion de poblacion celular heterogenea o mezclada en tumores - Google Patents
Eliminacion de poblacion celular heterogenea o mezclada en tumoresInfo
- Publication number
- CR9518A CR9518A CR9518A CR9518A CR9518A CR 9518 A CR9518 A CR 9518A CR 9518 A CR9518 A CR 9518A CR 9518 A CR9518 A CR 9518A CR 9518 A CR9518 A CR 9518A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tumors
- heterogenic
- elimination
- cell population
- eliminate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen metodos para eliminar o inhibir tumores que comprenden poblaciones celulares heterogeneas o mezcladas. La eliminacion o inhibicion de tumores se logra mediante el direccionamiento selectivo de un ligando unico que se supone que es expresado en una poblacion celular particular para eliminar tambien una poblacion celular que carece del ligando unico. Estos conjugados tienen uso terapeutico a medida que son suministrados a una poblacion celular especifica para eliminar esas celulas y el farmaco citotoxico es liberado para eliminar las celulas no de objetivo, eliminando de esta manera el tumor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67149805P | 2005-04-15 | 2005-04-15 | |
| US78172206P | 2006-03-14 | 2006-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9518A true CR9518A (es) | 2008-08-11 |
Family
ID=37115818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9518A CR9518A (es) | 2005-04-15 | 2007-11-14 | Eliminacion de poblacion celular heterogenea o mezclada en tumores |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060233814A1 (es) |
| EP (1) | EP1868649A4 (es) |
| JP (1) | JP2008538365A (es) |
| KR (1) | KR20070120156A (es) |
| CN (1) | CN102603770A (es) |
| AU (1) | AU2006236489C1 (es) |
| BR (1) | BRPI0608175A2 (es) |
| CA (1) | CA2618721A1 (es) |
| CR (1) | CR9518A (es) |
| EA (1) | EA200702239A1 (es) |
| IL (1) | IL186535A (es) |
| MX (1) | MX2007012817A (es) |
| NO (1) | NO20075245L (es) |
| WO (1) | WO2006113623A2 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011624A (es) * | 2002-05-24 | 2005-03-07 | Schering Corp | Anticuerpo neutralizante humano anti-igfr. |
| DK1578446T3 (en) * | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| EP2365001A3 (en) * | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| EP2281841A3 (en) * | 2004-12-03 | 2013-10-23 | Merck Sharp & Dohme Corp. | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
| AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| CN101222926B (zh) * | 2005-04-15 | 2013-07-17 | 默沙东公司 | 用于治疗或预防癌症的方法和组合物 |
| CA2678008C (en) | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
| EP1934261B1 (en) * | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
| AU2007212447B2 (en) * | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20100150950A1 (en) * | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| US9011864B2 (en) * | 2007-12-26 | 2015-04-21 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| US9446146B2 (en) | 2007-12-26 | 2016-09-20 | Biotest Ag | Methods and agents for improving targeting of CD138 expressing tumor cells |
| ES2475201T3 (es) * | 2007-12-26 | 2014-07-10 | Biotest Ag | Agentes dirigidos contra CD138 y usos de los mismos |
| PL2242772T3 (pl) * | 2007-12-26 | 2015-05-29 | Biotest Ag | Immunokonjugaty nakierowane na CD138 i ich zastosowanie |
| EP2279291B1 (en) | 2008-04-09 | 2019-07-03 | Cornell University | Coferons and methods of making and using them |
| AU2015202204A1 (en) * | 2008-04-30 | 2015-05-14 | Immunogen, Inc. | Cross-linkers and their uses |
| NZ588884A (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| JP5784592B2 (ja) | 2009-06-03 | 2015-09-24 | イミュノジェン・インコーポレーテッド | 抱合方法 |
| EP2485678A4 (en) | 2009-10-07 | 2013-04-03 | Univ Cornell | Coferons and methods of making and using them |
| AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
| CA2815277A1 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン, インコーポレイテッド | 非拮抗性egfr結合分子およびその免疫複合体 |
| EA033468B1 (ru) | 2011-03-29 | 2019-10-31 | Immunogen Inc | Способы получения конъюгата "антитело-майтансиноид" |
| WO2012177837A2 (en) | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| AU2015224535B2 (en) * | 2011-06-21 | 2017-07-20 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| JP2014533954A (ja) | 2011-11-21 | 2014-12-18 | イミュノジェン, インコーポレイテッド | Egfr抗体細胞傷害性薬物複合体による、egfr療法に耐性である腫瘍の治療方法 |
| US10117932B2 (en) | 2011-12-08 | 2018-11-06 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| EP2904089A4 (en) | 2012-10-04 | 2016-05-25 | Immunogen Inc | USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES |
| US9415118B2 (en) * | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CN105997942B (zh) * | 2016-06-24 | 2019-01-29 | 浙江大学 | 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用 |
| TWI744730B (zh) | 2018-12-04 | 2021-11-01 | 田德揚 | 用於遞送抗癌劑之立體複合物 |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
| WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| KR20060080535A (ko) * | 2003-05-14 | 2006-07-10 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| EP1651162B1 (en) * | 2003-05-20 | 2015-10-21 | ImmunoGen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
-
2006
- 2006-04-14 EA EA200702239A patent/EA200702239A1/ru unknown
- 2006-04-14 EP EP06750449A patent/EP1868649A4/en not_active Withdrawn
- 2006-04-14 WO PCT/US2006/014411 patent/WO2006113623A2/en not_active Ceased
- 2006-04-14 US US11/404,001 patent/US20060233814A1/en not_active Abandoned
- 2006-04-14 JP JP2008506808A patent/JP2008538365A/ja active Pending
- 2006-04-14 CN CN2012100312841A patent/CN102603770A/zh active Pending
- 2006-04-14 BR BRPI0608175-4A patent/BRPI0608175A2/pt not_active IP Right Cessation
- 2006-04-14 AU AU2006236489A patent/AU2006236489C1/en not_active Ceased
- 2006-04-14 CA CA002618721A patent/CA2618721A1/en not_active Abandoned
- 2006-04-14 KR KR1020077023581A patent/KR20070120156A/ko not_active Withdrawn
- 2006-04-14 MX MX2007012817A patent/MX2007012817A/es not_active Application Discontinuation
-
2007
- 2007-10-10 IL IL186535A patent/IL186535A/en not_active IP Right Cessation
- 2007-10-12 NO NO20075245A patent/NO20075245L/no unknown
- 2007-11-14 CR CR9518A patent/CR9518A/es not_active Application Discontinuation
-
2008
- 2008-08-05 US US12/186,411 patent/US8137669B2/en not_active Expired - Fee Related
-
2011
- 2011-09-09 US US13/229,422 patent/US8388960B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8388960B2 (en) | 2013-03-05 |
| AU2006236489B2 (en) | 2010-10-28 |
| WO2006113623A2 (en) | 2006-10-26 |
| IL186535A0 (en) | 2008-01-20 |
| AU2006236489A2 (en) | 2006-10-26 |
| EP1868649A4 (en) | 2011-06-29 |
| US8137669B2 (en) | 2012-03-20 |
| MX2007012817A (es) | 2007-12-12 |
| US20110319612A1 (en) | 2011-12-29 |
| IL186535A (en) | 2012-03-29 |
| CN102603770A (zh) | 2012-07-25 |
| NO20075245L (no) | 2008-01-14 |
| US20060233814A1 (en) | 2006-10-19 |
| EP1868649A2 (en) | 2007-12-26 |
| WO2006113623A3 (en) | 2008-09-12 |
| KR20070120156A (ko) | 2007-12-21 |
| AU2006236489A1 (en) | 2006-10-26 |
| CA2618721A1 (en) | 2006-10-26 |
| EA200702239A1 (ru) | 2008-10-30 |
| AU2006236489C1 (en) | 2012-04-12 |
| US20090076263A1 (en) | 2009-03-19 |
| JP2008538365A (ja) | 2008-10-23 |
| BRPI0608175A2 (pt) | 2009-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| GEP20104994B (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
| BRPI0416981A (pt) | compostos para tratamento de doenças proliferativas de célula | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| CL2009000133A1 (es) | Compuestos derivados de ftalazinona, inhibidores de la actividad parp; composicion farmaceutica; uso en el tratamiento de enfermedades vasculares, shock septico, lesion isquemica, neurotoxicidad, shock hemorragico, como auxiliar en la terapia del cancer de mama, de ovario, de pancreas, entre otras. | |
| CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
| MX2007010996A (es) | Nuevas composiciones de liposomas. | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| EA200900285A1 (ru) | Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов | |
| PE20120371A1 (es) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak | |
| CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
| MX2011012513A (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
| CL2009001476A1 (es) | Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular. | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
| CY1111240T1 (el) | Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1 | |
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |